Multidrug resistance reversal agents

Drugs of the Future

Volumn 22, Issue 2, 1997, Pages 149-158

  Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; BIBW 22 BS; BIRICODAR; CINCHONINE; CYCLOSPORIN A; DEXNIGULDIPINE; DEXVERAPAMIL; DIPYRIDAMOLE; ELACRIDAR; FLUPENTIXOL; GLYCOPROTEIN P; N (3,4 DIMETHOXYPHENETHYL) N METHYL 2 (2 NAPHTHYL) 1,3 DITHIANE 2 PROPYLAMINE; NICARDIPINE; NIFEDIPINE; PHENOTHIAZINE DERIVATIVE; PROGESTERONE; QUINIDINE; QUININE; TAMOXIFEN; TOREMIFENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030945267     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Biedler, J.L., Riehm, H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross resistance, radioautographic and cytogenetic studies. Cancer Res 1970, 30: 1174-84.
2. Danø, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973, 323: 466-83.
3. Juliano, R.L., Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1978, 455: 152-62.
4. Kartner, N., Riordan, J.R., Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221: 1285-9.
5. Kartner, N., Evernden-Porelle, D., Bradley, G., Ling, V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985, 316: 820-3.
6. Chen, C., Chin, J.E., Ueda, K. et al. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47: 381-9.
7. Roninson, I.B., Avelson, H.T., Housman, D.E., Howell, N., Varshavsky, A. Amplification of specific DNA sequences correlates with multidrug resistance in chinese hamster cells. Nature 1984, 309: 606-28.
8. Gerlach, J.H., Endicott J.A., Juranka, P.F. et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986, 324: 485-9.
9. Gros, P., Croop, J., Housman, D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47: 371-80.
10. Endicott, J.A., Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989, 58: 137-71.
11. Gottesman, M.M., Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62: 385-427.
12. Chin, J.E., Soffir, R., Noonan, K.E., Choi, K., Roninson, I.B. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989, 9: 3808-20.
13. Hsu, S.I.H., Lothstein, L., Horwitz, S.B. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 1989, 264: 12053-62.
14. Croop, J.M., Raymond, M., Haber, D. et al. The three mouse multidrug resistance genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9: 1346-50.
15. Bell, D.R., Trent, J.M., Willard, H.F., Riordan, J.R., Ling, V. Chromosomal location of human P-glycoprotein gene sequence. Cancer Genet Cytogenet 1987, 25: 141-8.
16. Ueda, K., Cardarelli, C., Gottesman, M.M., Pastan, I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 1987, 84: 3004-8.
17. Ruetz, S., Gros, P. Phosphatidylcholine translocase: A physiological role for the MDR2 gene. Cell 1994, 77: 1071-81.
18. De Isabella, P., Capranico, G., Zunino, F. The role of topoisomerase-II in drug resistance. Life Sci 1991, 48: 2195-205.
19. Cole, S.P.C., Bhardwaj, G., Gerlach, J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258: 1650-4.
20. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84: 7735-8.
21. Cordon-Cardo, C., O'Brien, J.P., Casals, D. et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86: 695-8.
22. Schinkel, A.H., Smit, J.J.M., van Tellingen, O. et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77: 491-502.
23. Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41: 1967-72.
24. Ford, J.M., Hait, W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 2: 155-99.
25. Georges, E., Sharom, F.J., Ling, V. Multidrug resistance and chemosensitization. Therapeutic implication for cancer chemotherapy. Adv Pharmacol 1990, 21: 185-220.
26. Zamora, J.M., Pearse, H.L., Beck, W.T. Physico-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988, 33: 454-62.
27. Huet, S., Robert, J. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels. Int J Cancer 1988, 41: 283-6.
28. Ford, J.M., Prozialeck, W.C., Hait, W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989, 35: 105-15.
29. Twentyman, P.R. Modifications of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br J Cancer 1988, 57: 254-8.
30. Gruber, A., Peterson, C., Reizenstein, P. D-Verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 1988, 41: 224-6.
31. Twentyman, P.R., Bleehen, N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991, 27A: 1639-42.
32. Pierré, A., Dunn, T.A., Kraus-Berthier, L. et al. In vitro and in vivo circumvention of multidrug resistance by Servier-9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 1992, 10: 137-48.
33. Hyafil, F., Vergely, C., Duvignaud, P., Grandperret, T. In vitro and in vivo reversal of multidrug resistance by GF-120918, an acridone-carboxamide derivative. Cancer Res 1993, 53: 4595-602.
34. Germann, U.A., Zelle, R.E., Shlyakhter, D. et al. VX-710: A novel agent for reversal of P-glycoprotein-mediated multidrug resistance. Proc Am Assoc Cancer Res 1995, 36: 346.
35. Safa, A.R. Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 1992, 10: 295-305.
36. Beck, W.T., Qian, X.D. Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 1992, 43: 89-93.
37. Bruggeman, E.P., Currier, S.J., Gottesman, M.M., Pastan, I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992, 267: 21020-6.
38. Tamai, I., Safa, A. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991, 266: 16796-800.
39. Greenberger, L.M., Lisanti, C.J., Silva, J.T., Horwitz, S.B. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1. J Biol Chem 1991, 266: 20744-51.
40. Scala, S., Akhmed , IM., Dickstein. B., Rao, U.S., Stein, W., Bates, S.E. Diversity in P-glycoprotein substrates and antagonists. Proc Am Assoc Cancer Res 1996, 37: 325.
41. Ayesh, S., Shao, Y.M., Stein, W.D. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1996, 1316: 8-18.
42. Borgnia, M.J., Eytan, G.D., Assaraf, Y.G. Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common O-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 1996, 271: 3163-71.
43. Basu, A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 1993, 59: 257-80.
44. Hu, Y.P., Robert, J. Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. J Cancer Res Clin Oncol, in press.
45. Schuurhuis, G.J., van Heijningen, T.H.M., Cervantes, A. et al. Changes in the subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993, 68: 898-908.
46. Bennis, S., Ichas, F., Robert, J. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukaemia cell line. Int J Cancer 1995 62: 283-90.
47. Muller, C., Bailly, J.D., Goubin, F. et al. Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int J Cancer 1994, 56: 749-54.
48. Hu, Y.P., Pourquier, P., Doignon, F., Crouzet, M., Robert, J. Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture. Anticancer Drugs 1996, 7: 738-44.
49. Chaudhary, P.M., Roninson, I.B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 1992, 4: 281-90.
50. Genne, P., Coudert, B., Pelletier, H., Girardot, C., Martin, F., Chauffert, B. Serum concentrations required for an in vivo modulation of anthracycline resistance by amiodarone. Anticancer Res 1989, 9: 1655-60.
51. Nielsen, D., Skovsgaard, T. P-glycoprotein as multidrug transporter. A critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1992, 1139: 169-83.
52. Galski, H., Sullivan, M., Willingham, M.C. et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia. Mol Cell Biol 1989, 9: 4357-63.
53. Mickisch, G.H., Merlino, G.T., Galski, H, Gottesman, M.M., Pastan, I. Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991, 88: 547-51.
54. Boesch, D., Gaveriaux C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P., Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Res 1991, 51: 4226-33.
55. Eliason, J.F., Sawada, R., Tsukaguchi, T. et al. The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB cell lines in vivo. Eur J Cancer 1995, 31A: 2354-61.
56. Durie, B.G.M., Dalton, W.S. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988, 68: 203-6.
57. Dalton, W.S., Grogan, T.M., Meltzer, P.S., Scheper, R.J., Salmon, S.E. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7: 415-24.
58. Linn, S.C., Giaccone, G., Pinedo, H.M. Complete remission of metastatic colorectal cancer: A pitfall in a multidrug resistance reversal trial. Lancet 1994, 343: 1648-9.
59. Bartlett, N.L., Lum, B.L., Fischer, G.A. et al. Phase I trial of doxorubicin with cyclosporin A as a modulator of multidrug resistance. J Clin Oncol 1994, 12: 835-42.
60. Yahanda, A.M., Adler, K.M., Fischer, G.A. et al. Phase I trial of etoposide with cyclosporin A as a modulator of multidrug resistance. J Clin Oncol 1992, 10: 1635-42.
61. Ozols, R.F., Cunnion, R.E., Klecker, R.W. et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5: 641-7.
62. Salmon, S.E., Dalton, W.S., Grogan, T.M. et al. Multidrug-resistant myeloma. Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991, 78: 44-50.
63. Miller, T.P., Grogan, T.M., Dalton, W.S., Spier, C.M., Scheper, R.J., Salmon, S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991, 9: 17-24.
64. Trumper, L.H., Ho, A.D., Wulf, G., Hunstein, W. Addition of verapamil to overcome multidrug resistance in multiple myeloma: Preliminary clinical observations in 10 patients. J Clin Oncol 1989, 7: 1578-83.
65. Mertens, M., Thomas, L., Lelie, J.V.D. Lack of reversal of with verapamil of drug resistance in multiple myeloma. Br J Haematol 1990, 76: 155-8.
66. Dalton, W.S., Crowley, J.J., Fojo, A. et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. Cancer 1995, 75: 815-20.
67. Demicheli, R., Jirillo, A., Bonciarelli, G., Lonardi, F., Balli, M., Bandello, A. 4′-Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori 1989, 75: 245-7.
68. Langenbuch, T., Mross, K., Jonat, W., Hassfeld, D.K. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 1990, 26: 93-6.
69. Hendrick, A.M., Harris, A.L., Cantwell, B.M.J. Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Ann Oncol 1991, 2: 71-2.
70. Mross, K., Bohn, C., Edler, L. et al. Randomized phase II study of single agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. Ann Oncol 1993, 4: 45-50.
71. Millward, M.J., Cantwell, B.M.J., Munroe, N.C., Robinson, A., Corris, P.A., Harris, A.L. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: A randomised study. Br J Cancer 1993, 67: 1031-5.
72. Cairo, M.S., Siegel, S., Sender, L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989, 49: 1063-6.
73. Scheithauer, W., Kornek, G., Kastner, J. et al. Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur J Cancer 1993, 29A: 2337-8.
74. Motzer, R.J., Lyn, P., Fischer, P. et al. Phase I/II of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995, 13: 1958-65.
75. Wilson, W.H., Bates, S.E., Fojo, A. et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13: 1995-004.
76. Kerr, D.J., Graham, J., Cummings, J. et al. The effects of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1987, 18: 239-42.
77. Tolcher, A.W., Cowan, K.H., Solomon, D. et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996, 14: 1173-84.
78. Mross, K., Hamm, K., Hossfeld, D.K. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 1993, 31: 369-75.
79. Miller, R.L., Bukowski, R.M., Budd, G.T. et al. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine: A phase I/II trial. J Clin Oncol 1988, 6: 880-8.
80. Sridhar, K.S., Krishan, A., Samy, T.S.A. et al. Phase I and pharmacokinetic studies of prochlorperazine 2-hr IV infusion as a doxorubicin-efflux blocker. Cancer Chemother Pharmacol 1994, 34: 377-84.
81. Sonneveld, P., Durie, B.G.M., Lockhorst, H.M. et al. Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 1992, 340: 255-9.
82. List, A.F., Spier, C., Greer, J. et al. Phase I/II trial of cyclosporin A as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993, 11: 1624-34.
83. Rodenburg, C.J., Nooter, K., Herweijer, H. et al. Phase II study combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991, 2: 305-6.
84. Verweij, J., Herweijer, H., Oosterom, R. et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin A in an attempt to reverse multidrug resistance. Br J Cancer 1991, 64: 361-4.
85. Sarris, A.H., Younes, A., McLaughlin, P. et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodkin's lymphoma. J Clin Oncol 1996 14: 233-9.
86. Lum, B.L., Kaubisch, S., Yahanda, A.M. et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a Phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10: 1635-42.
87. Rushing, D.A., Raber, S.R., Rodvold, K.A., Piscitelli, S.C., Plank, G.S., Tewksbury, D.A. The effect of cyclosporin on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994, 74: 834-41.
88. Fischer, G.A., Bartlett, N.L., Lum, N.A. et al. Phase I trial of taxol with high-dose cyclosporin A as a modulator of multidrug resistance. Proc Am Soc Clin Oncol 1994, 13: 144.
89. Boote, D.J., Dennis, I.F., Twentyman, P.R. et al. Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996, 14: 610-8.
90. Sonneveld, P., Marie, J.P., Huisman, C. et al. Reversal of multidrug resistance by SDZ PSC-833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996, 10: 1741-50.
91. Wishart, C.C., Bissett, D., Paul, J. et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994, 12: 1271-7.
92. Wishart, G.C., Plumb, J.A., Morrison, J.G., Hamilton, T.G., Kaye, S.B. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 1992, 28: 28-31.
93. Solary, E., Caillot, D., Chauffert, B. et al. Feasibility of using quinine, a potential multidrug resistance reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992, 10: 1730-6.
94. Solary, E., Witz, B., Caillot, D. et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 1996, 88: 1198-205.
95. Genne, P., Dimanche-Boitrel, M.T., Mauvernay, R.Y. et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992, 52: 2797-801.
96. Trump, D.L., Smith, D.C., Ellis, P.G. et al. High-dose oral tamoxifen, a potential multidrug-resistance reversal agent. Phase I that in combination with vinblastine. J Natl Cancer Inst 1992, 84: 1811-6.
97. Millward, M.J., Cantwell, B.M.J., Lien, E.A., Carmichael, J., Harris, A.L. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992, 28A: 805-10.
98. Beck, W.T., Grogan, T.M., Willman, C.L. et al. Methods to detect P-glycoprotein-asociated multidrug resistance in patients tumors: Consensus recommendations. Cancer Res 1996, 56: 3010-20.
99. Marie, J.P., Faussat, A.M., Huet, S. et al. Multicentricevaluation of the MDR phenotype in leukemia. Leukemia, in press.
100. Lehnert, M. Dalton, W.S., Roe, D., Emerson, S., Salmon, S.E. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991, 77: 348-54.
101. Osann, K., Sweet, P., Slater, L.M. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 1992, 30: 152-4.
102. Mechetner, E.B., Roninson, I.B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992, 89: 5824-8.
103. Thierry, A.R., Rahman, A., Dritschilo, A. Overcoming multidrug resistance in human tumor cells using free and liposomally-encapsulated antisense oligodeoxy-nucleotides. Biochem Biophys Res Commun 1993, 190: 952-60.
104. Barrand, M.A., Rhodes, T., Center, M.S., Twentyman, P.R. Chemosensitisation and drug drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 kDa membrane protein distinct from P-glycoprotein. Eur J Cancer 1993, 29A: 408-15.
105. Versantvoort, C.H.M., Schuurhuis, G.J., Pinedo, H.M. et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 1993, 68: 939-46.
106. Sato, W., Fukazawa, N., Nakanishi, O. et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995, 35: 271-7.
107. Schneider, E., Yamazaki, H., Sinha, B.K., Cowan, K.H. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF-7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Br J Cancer 1995, 71: 738-43.
108. Robert, J. Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Res 1994, 14: 2371-4.